Chronic inflammation in the pathogenesis of benign prostatic hyperplasia

International Journal of Andrology

Volumn 33, Issue 3, 2010, Pages 475-488

  Fibbi, B ^a   Penna, G ^b   Morelli, A ^a   Adorini, L ^b   Maggi, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

Benign prostatic hyperplasia; Chronic inflammation; Stromal cells; Vitamin D receptor agonists

Indexed keywords

CALCITRIOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; ELOCALCITOL; ESTRADIOL; FINASTERIDE; IMMUNOMODULATING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR AGONIST;

ANTIINFLAMMATORY ACTIVITY; CELL PROLIFERATION; CELL TYPE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONSTIPATION; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; HYPERCALCEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MEDIATOR RELEASE; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW; STROMA CELL; TACHYCARDIA; TH1 CELL; TH17 CELL; URINARY TRACT INFECTION; VITAMIN METABOLISM; XEROSTOMIA;

ANDROGENS; ANTI-INFLAMMATORY AGENTS; CALCITRIOL; CHEMOKINES; CHRONIC DISEASE; CYTOKINES; HUMANS; INFLAMMATION; INTERLEUKIN-8; MALE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATITIS; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 77951918078     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2009.00972.x     Document Type: Review

References (145)

1. Adorini, L. Penna, G. (2008) Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 4, 404 412.
2. Adorini, L., Penna, G., Amuchastegui, S., Cossetti, C., Aquilano, F., Mariani, R. et al. (2007) Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). Journal of Steroid Biochemistry and Molecular Biology 103, 689 693.
3. Alexander, R. B., Brady, F. Ponniah, S. (1997) Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology 50, 893 899.
4. Alexander, R. B., Mann, D. L., Borkowski, A. A., Fernandez-Vina, M., Klyushnenkova, E. N., Kodak, J., Propert, K. J. Kincaid, M. (2004) Granulomatous prostatitis linked to HLA-DRB1*1501. Journal of Urology 171, 2326 2329.
5. Ali, M. M. Vaidya, V. (2007) Vitamin D and cancer. J Cancer Res Ther 3, 225 230.
6. 3 levels: the role of renal synthesis and catabolism of vitamin D. Journal of Steroid Biochemistry and Molecular Biology 89-90, 111 113.
7. Andersson, K. E. (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3, 46 53.
8. Ayala, G., Tuxhorn, J. A., Wheeler, T. M., Frolov, A., Scardino, P. T., Ohori, M., Wheeler, M., Spitler, J. Rowley, D. R. (2003) Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clinical Cancer Research 9, 4792 4801.
9. Barni, T., Vannelli, B. G., Sadri, R., Pupilli, C., Ghiandi, P., Rizzo, M., Selli, C., Serio, M. Fiorelli, G. (1994) Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: gene expression and its cellular localization. Journal of Clinical Endocrinology and Metabolism 78, 778 783.
10. Batstone, G. R., Doble, A. Gaston, J. S. (2002) Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clinical and Experimental Immunology 128, 302 307.
11. Beadling, C. Slifka, M. K. (2006) Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Archivum Immunologiae et Therapiae Experimentalis (Warsz) 54, 15 24.
12. Bedalov, G., Vucković, I., Fridrih, S., Bruk, M., Puskar, D. Bartolin, Z. (1994) Prostatitis in benign prostatic hyperplasia: a histological, bacteriological and clinical study. Acta Medica Croatica 48, 105 109.
13. Beer, T. M., Javle, M., Lam, G. N., Henner, W. D., Wong, A. Trump, D. L. (2005) Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clinical Cancer Research 11, 7794 7799.
14. Beer, T. M., Ryan, C. W., Venner, P. M., Petrylak, D. P., Chatta, G. S., Ruether, J. D., Chi, K. N., Young, J., Henner, W. D. ASCENT(AIPC Study of Calcitriol ENhancing Taxotere) Investigators 2008) Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112, 326 330.
15. Bierhoff, E., Walljasper, U., Hofmann, D., Vogel, J., Wernert, N. Pfeifer, U. (1997) Morphological analogies of fetal prostate stroma and stromal nodules in BPH. Prostate 31, 234 240.
16. Boget, S., Cereser, C., Parvaz, P., Leriche, A. Revol, A. (2001) Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are not. European Journal of Endocrinology 145, 303 310.
17. Braunersreuther, V., Mach, F. Steffens, S. (2007) The specific role of chemokines in atherosclerosis. Thrombosis and Haemostasis 97, 714 721.
18. Carlberg, C. Polly, P. (1998) Gene regulation by vitamin D3. Critical Reviews in Eukaryotic Gene Expression 8, 19 42.
19. Castro, P., Xia, C., Gomez, L., Lamb, D. J. Ittmann, M. (2004) Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 60, 153 159.
20. Claus, S., Berges, R., Senge, T. Schulze, H. (1997) Cell kinetic in epithelium and stroma of benign prostatic hyperplasia. Journal of Urology 158, 217 221.
21. Colli, E., Rigatti, P., Montorsi, F., Artibani, W., Petta, S., Mondaini, N. et al. (2006) BXL-628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. European Urology 49, 82 86.
22. Colli, E., Digesu, G. A. Olivieri, L. (2007) Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs 16, 999 1007.
23. Corman, J. M., Sercarz, E. E. Nanda, N. K. (1998) Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clinical and Experimental Immunology 114, 166 172.
24. Crescioli, C., Maggi, M., Vannelli, G. B., Luconi, M., Salerno, R., Barni, T., Gulisano, M., Forti, G. Serio, M. (2000) Effect of a vitamin D3 analog on keratinocyte growth factor-induced cell proliferation in benign prostatic hyperplasia. Journal of Clinical Endocrinology and Metabolism 85, 2576 2583.
25. Crescioli, C., Ferruzzi, P., Caporali, A., Scaltriti, M., Bettuzzi, S., Mancina, R. et al. (2004) Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. European Journal of Endocrinology 150, 591 603.
26. Crescioli, C., Morelli, A., Adorini, L., Ferruzzi, P., Luconi, M., Vannelli, G. B. et al. (2005) Human bladder as a novel target for vitamin D receptor ligands. Journal of Clinical Endocrinology and Metabolism 90, 962 972.
27. D'Ambrosio, D., Cippitelli, M., Cocciolo, M. G., Mazzeo, D., Di Lucia, P., Lang, R., Sinigaglia, F. Panina-Bordignon, P. (1998) Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. Journal of Clinical Investigation 101, 252 262.
28. De Bellis, A., Crescioli, C., Grappone, C., Dilani, S., Ghiandi, P., Forti, G. Serio, M. (1998) Expression and cellular localization of keratinocyte growth factor and its receptor in human hyperplastic prostate tissue. Journal of Clinical Endocrinology and Metabolism 83, 2186 2191.
29. De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B. Nelson, W. G. (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7, 256 269.
30. DeLuca, H. F. (2004) Overview of general physiologic features and functions of vitamin D. American Journal of Clinical Nutrition 80, 1689S 1696S.
31. Deshmukh, N., Scotson, J., Dodson, A. R., Smith, P. H., Ke, Y. Foster, C. S. (1997) Differential expression of acidic and basic fibroblast growth factors in benign prostatic hyperplasia identified by immunohistochemistry. British Journal of Urology 80, 869 874.
32. Deshpande, N., Hallowes, R. C., Cox, S., Mitchell, I., Hayward, S. Towler, J. M. (1989) Divergent effects of interferons on the growth of human benign prostatic hyperplasia cells in primary culture. Journal of Urology 141, 157 160.
33. Di Silverio, F., Gentile, V., De Matteis, A., Mariotti, G., Giuseppe, V., Luigi, P. A. Sciarra, A. (2003) Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. European Urology 43, 164 175.
34. Donjacour, A. A. Cunha, G. R. (1991) Stromal regulation of epithelial function. Cancer Treatment and Research 53, 335 364.
35. Dunphy, E. J., Eickhoff, J. C., Muller, C. H., Berger, R. E. McNeel, D. G. (2004) Identification of antigen-specific IgG in sera from patients with chronic prostatitis. Journal of Clinical Immunology 24, 492 502.
36. Eaton, C. L. (2003) Aetiology and pathogenesis of benign prostatic hyperplasia. Current Opinion in Urology 13, 7 10.
37. Fitzpatrick, J. M. (2006) The natural history of benign prostatic hyperplasia. BJU Int 97, 3 6.
38. Giri, D. Ittmann, M. (2000) Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. American Journal of Pathology 157, 249 255.
39. Giri, D. Ittmann, M. (2001) Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. American Journal of Pathology 159, 139 147.
40. Giri, D., Ozen, M. Ittman, M. (2001) Interleukin-6 is an autocrine growth factor in human prostate cancer. American Journal of Pathology 159, 2159 2165. (Pubitemid 33104270)
41. Gregori, S., Casorati, M., Amuchastegui, S., Smiroldo, S., Davalli, A. M. Adorini, L. (2001) Regulatory T cells induced by 1α,25-Dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. Journal of Immunology 167, 1945 1953.
42. Griffin, M. D., Lutz, W., Phan, V. A., Bachman, L. A., McKean, D. J. Kumar, R. (2001) Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 22, 22.
43. Handisurya, A., Steiner, G. E., Stix, U., Ecker, R. C., Pfaffeneder-Mantai, S., Langer, D., Kramer, G., Memaran-Dadgar, N. Marberger, M. (2001) Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate 49, 251 262.
44. Harrington, L. E., Mangan, P. R. Weaver, C. T. (2006) Expanding the effector CD4 T-cell repertoir: The Th17 lineage. Current Opinion in Immunology 18, 349 356.
45. Harris, M. T., Feldberg, R. S., Lau, K. M., Lazarus, N. H. Cochrane, D. E. (2000) Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate 44, 19 25.
46. Harzstark, A. L. Ryan, C. J. (2008) Novel therapeutic strategies in development for prostate cancer. Expert Opin Investig Drugs 17, 13 22.
47. Ho, E., Boileau, T. W. M. Bray, T. M. (2004) Dietary influences on endocrine-inflammatory interactions in prostate cancer development. Archives of Biochemistry and Biophysics 428, 109 117.
48. Ishigooka, M., Hayami, S., Hashimoto, T., Suzuki, Y., Katoh, T. Nakada, T. (1996) Relative and total volume of histological components in benign prostatic hyperplasia: relationships between histological components and clinical findings. Prostate 29, 77 82.
49. Jacobsen, S. J., Girman, C. J., Guess, H. A., Rhodes, T., Oesterling, J. E. Lieber, M. M. (1996) Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. Journal of Urology 155, 595 600.
50. Jacobsen, S. J., Jacobson, D. J., Girman, C. J., Roberts, R. O., Rhodes, T., Guess, H. A. Lieber, M. M. (1997) Natural history of prostatism: risk factors for acute urinary retention. Journal of Urology 158, 481 487. (Pubitemid 27327692)
51. Janssen, M., Albrecht, M., Möschler, O., Renneberg, H., Fritz, B., Aumüller, G. Konrad, L. (2000) Cell lineage characteristics of human prostatic stromal cells cultured in vitro. Prostate 43, 20 30.
52. Jones, G., Strugnell, S. A. DeLuca, H. F. (1998) Current understanding of the molecular actions of vitamin D. Physiological Reviews 78, 1193 1231.
53. Klyushnenkova, E. N., Link, J., Oberle, W. T., Kodak, J., Rich, C., Vandenbark, A. A. Alexander, R. B. (2005) Identification of HLA-DRB1*1501- restricted T-cell epitopes from prostate-specific antigen. Clinical Cancer Research 11, 2853 2861.
54. Kobayashi, Y. (2008) The role of chemokines in neutrophil biology. Front Biosci 13, 2400 2407.
55. Kohnen, P. W. Drach, G. W. (1979) Patterns of inflammation in prostatic hyperplasia: a hustologic and bacteriologic study. Journal of Urology 121, 755 760.
56. Kolman, C., Girman, C. J., Jacobsen, S. J. Lieber, M. M. (1999) Distribution of post-void residual urine volume in randomly selected men. Journal of Urology 161, 122 127.
57. Konig, J. E., Senge, T., Allhoff, E. P. Konig, W. (2004) Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 58, 121 129.
58. Kramer, G. Marberger, M. (2006) Could inflammation be a key component in the progression of benign prostatic hyperplasia? Current Opinion in Urology 16, 25 29.
59. Kramer, G., Steiner, G. E., Handisurya, A., Stix, U., Haitel, A., Knerer, B., Gessl, A., Lee, C. Marberger, M. (2002) Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 52, 43 58.
60. Kramer, G., Steiner, G. E., Sokol, P., Mallone, R., Amann, G. Marberger, M. (2003) Loss of CD38 correlates with simultaneous up-regulation of human leukocyte antigen-DR in benign prostatic glands, but not in fetal or androgen-ablated glands, and is strongly related to gland atrophy. BJU Int 91, 409 416.
61. Kramer, G., Mitteregger, D. Marberger, M. (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European Urology 51, 1202 1216.
62. Krieger, J. N., Lee, S. W., Jeon, J., Cheah, P. Y., Liong, M. L. Riley, D. E. (2008) Epidemiology of prostatitis. International Journal of Antimicrobial Agents 31, S85 S90.
63. Lee, K. L. Peehl, D. M. (2004) Molecular and cellular pathogenesis of benign prostatic hyperplasia. Journal of Urology 172, 1784 1791.
64. Lin, V. K., Wang, D., Lee, I. L., Vasquez, D., Fagelson, J. E. McConnell, J. D. (2000) Myosin heavy chain gene expression in normal and hyperplastic human prostate issue. Prostate 44, 193 203.
65. MacDermott, R. P. (2007) Chemokines in the inflammatory bowel diseases. Journal of Clinical Immunology 19, 266 272.
66. Maggi, M., Crescioli, C., Morelli, A., Colli, E. Adorini, L. (2006) Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). Journal of Endocrinological Investigation 29, 665 674.
67. McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L. Jr., Dixon, C. M., Kusek, J. W. et al. (2003) The long term effect of doxazosine, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine 349, 2387 2398.
68. McKenzie, B. S., Kastelein, R. A. Cua, D. J. (2006) Understanding the IL-23-IL-17 immune pathway. Trends in Immunology 27, 17 23.
69. McNeal, J. (1990) Pathology of benign prostatic hyperplasia. Insight into etiology. Urologic Clinics of North America 17, 477 486.
70. McVary, K. T. (2006) BPH: epidemiology and comorbidities. Am J Manag Care 12, S122 S128.
71. Montaner, S., Perona, R., Saniger, L. Lacal, J. C. (1998) Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. Journal of Biological Chemistry 273, 12779 12785.
72. Montorsi, F. Colli, E. (2008) Elocalcitol in the Treatment of Bph: A Multicenter, Randomized, Placebo-Controlled Phase Iib Clinical Trial. Abstract at the American Urological Association Meeting.
73. Morelli, A., Vignozzi, L., Filippi, S., Vannelli, G. B., Ambrosiani, S., Mancina, R. et al. (2007) BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/ROCK signaling in rat and human bladder. Prostate 67, 234 247.
74. Mori, H., Maki, M., Oishi, K., Jaye, M., Igarashi, K., Yoshida, O. Hatanaka, M. (1990) Increased expression of genes for basic fibroblast growth factor and transforming growth factor type beta 2 in human benign prostatic hyperplasia. Prostate 16, 71 80.
75. Motrich, R. D., Maccioni, M., Molina, R., Tessera, A., Oledo, J., Riera, C. M. Rivero, V. E. (2005) Presence of IFNγ-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol 116, 149 157.
76. Naito, Y., Ito, M., Watanabe, T. Suzuki, H. (2005) Biomarkers in patients with gastric inflammation: a systematic review. Digestion 72, 164 180.
77. Napgal, S., Na, S. Rathnachalam, R. (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26, 662 687.
78. Naslund, M. J. Coffey, D. S. (1986) The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth J Urol 136, 1136 1140.
79. Nickel, J. C. (1994) Prostatic inflammation in benign prostatic hyperplasia-the third component? Can J Urol 1, 1 4.
80. Nickel, J. C. (2006) The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Current Opinion in Urology 16, 5 10.
81. Nickel, J. C. (2008) Inflammation and benign prostatic hyperplasia. Urol Clin N Am 35, 109 115.
82. Nickel, J. C., Downey, J., Young, I. Boag, S. (1999) Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 84, 976 981.
83. Nickel, J. C., Downey, J., Pontari, M. A., Shoskes, D. Zeitlin, S. I. (2004) A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int 93, 991 995.
84. Nickel, J. C., Roehrborn, C. G., O'Leary, M. P., Bostwick, D. G., Somerville, M. C. Rittmaster, R. S. (2007) The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. European Urology 54, 1379 1384.
85. Numerof, R. P. Asadullah, K. (2006) Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs 20, 93 103.
86. Odunjo, E. O. Elebute, E. A. (1971) Chronic prostatitis in benign prostatic hyperplasia. British Journal of Urology 43, 333 337.
87. Overbergh, L., Decallonne, B., Valckx, D., Verstuyf, A., Depovere, J. Laureys, J. (2000) Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clinical and Experimental Immunology 120, 139 146.
88. Paradowska, A., Maślińiski, W., Grzybowska-Kowalczyk, A. Łacki, J. (2007) The function of interleukin 17 in the pathogenesis of rheumatoid arthritis. Archivum Immunologiae et Therapiae Experimentalis (Warsz) 55, 329 334.
89. Pease, J. E. Sabroe, I. (2002) The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 1, 19 25.
90. Peehl, D. M. Sellers, R. G. (1997) Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Experimental Cell Research 232, 208 215.
91. Penna, G., Amuchastegui, S., Cossetti, C., Aquilano, F., Mariani, R., Sanvito, F., Dogliosi, C. Adorini, L. (2006) Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. Journal of Immunology 177, 8504 8511.
92. Penna, G., Mondaini, N., Amuchastegui, S., Degli Innocenti, S., Carini, M., Giubilei, G., Fibbi, B., Colli, E., Maggi, M. Adorini, L. (2007) Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. European Urology 51, 524 533.
93. Penna, G., Fibbi, B., Amuchastegui, S., Corsiero, E., Laverny, G., Silvestrini, E. et al. (2009a) The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kB pathways. Prostate 69, 480 493.
94. Penna, G., Fibbi, B., Amuchastegui, S., Cossetti, C., Aquilano, F., Laverny, G., Gacci, M., Crescioli, C., Maggi, M. Adorini, L. (2009b) Human Benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. Journal of Immunology 182, 4056 4064.
95. Perona, R., Montaner, S., Saniger, L., Sanchez-Perez, I., Bravo, R. Lacal, J. C. (1997) Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes and Development 11, 463 475.
96. Persson, B. E. Ronquist, G. (1996) Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. Journal of Urology 155, 958 960.
97. Peters, S. L., Schmidt, M. Michel, M. C. (2006) Rho kinase: a target for treating urinary bladder dysfunction? Trends in Pharmacological Sciences 27, 492 497.
98. Pinette, K. V., Yee, Y. K., Amegadzie, B. Y. Nagpal, S. (2003) Vitamin D receptor as a drug discovery target. Mini Rev Med Chem 3, 193 204.
99. Planz, B., Aretz, H. T., Wang, Q., Tabatabaei, S., Kirley, S. D., Lin, C. W. McDougal, W. S. (1999) Immunolocalization of the keratinocyte growth factor in benign and neoplastic human prostate and its relation to androgen receptor. Prostate 41, 233 242.
100. Ponniah, S., Arah, I. Alexander, R. B. (2000) PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain sindrome. Prostate 44, 49 54.
101. Pontari, M. A. Ruggieri, M. R. (2008) Mechanisms in prostatitis/chronic pelvic pain syndrome. Journal of Urology 179, S61 S67.
102. Price, H., McNeal, J. E. Stamey, T. A. (1990) Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Human Pathology 21, 578 585.
103. Prins, G. S. Korach, K. S. (2008) The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 73, 233 244.
104. Proost, P., Wuyts, A. van Damme, J. (1996) The role of chemokines in inflammation. International Journal of Clinical and Laboratory Research 26, 211 223.
105. Rautajoki, K. J., Kylaniemi, M. K., Raghav, S. K., Rao, K. Lahesmaa, R. (2008) An insight into molecular mechanisms of human T helper cell differentiation. Annals of Medicine 40, 322 335.
106. Roberts, R. O., Jacobsen, S. J., Jacobsen, D. J., Rhodes, T., Girman, C. J. Lieber, M. M. (2000) Longitudinal changes in peak urinary flow rates in a community based cohort. Journal of Urology 163, 107 113.
107. Robinette, C. L. (1988) Sex-hormone-induced inflammation and fibromuscolar proliferation in the rat lateral prostate. Prostate 12, 271 286.
108. Roehrborn, C. G. (2006) Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 97, 734 741.
109. Roehrborn, C. G. (2008) Pathology of benign prostatic hyperplasia. International Journal of Impotence Research 20, S11 S18.
110. Roehrborn, C. G., Siami, P., Barkin, J., Damião, R., Major-Walker, K., Morrill, B., Montorsi, F. CombAT Study Group 2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. Journal of Urology 179, 616 621.
111. Ropiquet, F., Giri, D., Lamb, D. J. Ittman, M. (1999) FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. Journal of Urology 162, 595 599.
112. Royuela, M., de Miguel, M. P., Bethencourt, F. R., Sánchez- Chapado, M., Fraile, B., Arenas, M. I. Paniagua, R. (2001) Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. Journal of Endocrinology 168, 447 454.
113. Rumpold, H., Untergasser, G., Madersbacher, S. Berger, P. (2002) The development of benign prostatic hyperplasia by trans-differentiation of prostatic stromal cells. Experimental Gerontology 37, 1001 1004.
114. Sandhu, J. S. (2008) Prostate cancer and chronic prostatitis. Curr Urol Rep 9, 328 332.
115. Schauer, I. G., Ressler, S. J., Tuxhorn, J. A., Dang, T. D. Rowley, D. R. (2008) Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 72, 205 213.
116. Schmeck, B., Brunsch, M., Seybold, J., Krull, M., Eichel-Streiber, C. Suttorp, N. (2003) Rho protein inhibition blocks cyclooxygenase-2 expression by proinflammatory mediators in endothelial cells. Inflammation 27, 89 95.
117. Schwartz, G. G. (2005) Vitamin D and the epidemiology of prostate cancer. Semin Dial 18, 276 289.
118. Sciarra, A., Di Silverio, F., Salsiccia, S., Autran Gomez, A. M., Gentilucci, A. Gentile, V. (2007) Inflammation and chronic prostatic diseases: evidence for a link? European Urology 52, 964 972.
119. Sciarra, A., Mariotti, G., Salciccia, S., Gomez, A. A., Monti, S., Toscano, V. Di Silverio, F. (2008) Prostate growth and inflammation. Journal of Steroid Biochemistry and Molecular Biology 108, 254 260.
120. Segain, J. P., Raingeard de la Bletiere, D., Sauzeau, V., Bourreille, A., Hilaret, G. Cario-Toumaniantz, C. (2003) Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: Evidence in Crohn's disease and experimental colitis. Gastroenterology 124, 1180 1187.
121. Sherwood, E. R., Fong, C. J., Lee, C. Kozlowski, J. M. (1992) Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate. Endocrinology 130, 2955 2963.
122. Shortliffe, L. M., Werner, N. Stamey, T. A. (1981) The detection of a local prostatic immunologic response to bacterial prostatitis. Journal of Urology 125, 509 515.
123. St Sauver, J. L., Jacobson, D. J., McGree, M. E., Lieber, M. M. Jacobson, S. J. (2006) Protective association between nonsteroidal anti-inflammatory drug use and measures of benign prostatic hyperplasia. American Journal of Epidemiology 164, 760 768.
124. Steiner, G., Gessl, A., Kramer, G., Schöllhammer, A., Förster, O. Marberger, M. (1994) Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. Journal of Urology 151, 480 484.
125. Steiner, G. E., Djavan, B., Kramer, G., Handisurya, A., Newman, M., Lee, C. Marberger, M. (2002) The picture of the prostatic lymphokine network is becoming increasingly complex. Rev Urol 4, 171 177.
126. Steiner, G. E., Stix, U., Handisurya, A., Willheim, M., Haitel, A., Reithmayr, F. et al. (2003) Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Laboratory Investigation 83, 1131 1146.
127. Story, M. T., Livingston, B., Baeten, L., Swartz, S. J., Jacobs, S. C., Begun, F. P. Lawson, R. K. (1989) Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 15, 355 365.
128. Straub, R. H. (2007) The complex role of estrogens in inflammation. Endocrine Reviews 28, 521 574.
129. Sutcliffe, S., Giovannucci, E., De Marzo, A. M., Willett, W. C. Platz, E. A. (2005) Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. American Journal of Epidemiology 162, 898 906.
130. Takechi, S., Yokoyama, M., Tanji, N., Nishio, S. Araki, N. (1999) Nonbacterial prostatitis caused by partial urethral obstruction in the rat. Urological Research 27, 346 350.
131. Theyer, G., Kramer, G. Assmann, I. (1992) Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Laboratory Investigation 66, 96 107.
132. Tinker, A. C. Wallace, A. V. (2006) Selective inhibitors of inducible nitric oxide synthase: potential agents for the treatment of inflammatory diseases? Curr Top Med Chem. 6, 77 92.
133. Trump, D. L., Potter, D. M., Muindi, J., Brufsky, A. Johnson, C. S. (2006) Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 106, 2136 2142.
134. Untergasser, G., Madersbacher, S. Berger, P. (2005) Benign prostatic hyperplasia: age-related tissue remodeling. Experimental Gerontology 40, 121 128.
135. Vykhovanets, E. V., Resnick, M. I. Marengo, S. R. (2005) The healthy rat prostate contains high levels of natural killer-like cells and unique subsets of CD4+ helper-inducer T cells: implications for prostatitis. Journal of Urology 173, 1004 1010.
136. Vykhovanets, E. V., Resnick, M. I., MacLennan, G. T. Gupta, S. (2007) Experimental rodent models of prostatitis: limitations and potential. Prostate Cancer Prostatic Dis 10, 15 29.
137. Wang, W., Bergh, A. Damber, J. E. (2004) Chronic inflammation in benign prostatic hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61, 60 72.
138. Waugh, D. J. Wilson, C. (2008) The interleukin-8 pathway in cancer. Clinical Cancer Research 14, 6735 6741.
139. Weidner, W., Schiefer, H. G., Krauss, H., Jantos, C., Friedrich, H. J. Altmannsberger, M. (1991) Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection 19, S119 S125.
140. Whitmore, W. F. Gittes, R. F. (1977) Studies on the prostate and testis as immunologically privileged sites. Cancer Treat Rep 61, 217 222.
141. Wilkinson, P. C. Liew, F. Y. (1995) Chemoattraction of human blood T lymphocytes by interleukin-15. Journal of Experimental Medicine 181, 1255 1259.
142. Wynn, T. A. (2004) Fibrotic disease and the T(H)1/T(H)2 paradigm. Nature Reviews. Immunology 4, 583 594.
143. Zhao, D., Kuhnt-Moore, S., Zeng, H., Pan, A., Wu, J. S. Simeonidis, S. (2002) Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves Rho family small GTPases. Biochemical Journal 368, 665 672.
144. Zhao, D., Kuhnt-Moore, S., Zeng, H., Wu, J. S., Moyer, M. P. Pothoulakis, C. (2003) Neurotensin stimulates IL-8 expression in human colonic epithelial cells through Rho GTPase-mediated NF-kappa B pathways. American Journal of Physiology. Cell Physiology 284, C1397 C1404.
145. Zisman, A., Zisman, E., Lindner, A., Velikanov, S., Siegel, Y. I. Mozes, E. (1995) Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. Journal of Urology 154, 1052 1055.